Related Experiment Video
Updated: Jul 21, 2026

A Rhodopsin Transport Assay by High-Content Imaging Analysis
Published on: January 16, 2019
Retinal Screening for Risdiplam-Related Toxicity in Infants With Presymptomatic Spinal Muscular Atrophy: Evidence for
Anna Waldie1, Morgan Kennedy2, Kimberley Tan3
1Ophthalmology Registrar, Sydney Children's Hospital, The University of Sydney, Sydney, Australia.
Insights
Cystoid macular edema (CME) was observed in 25% of infants with spinal muscular atrophy (SMA). These retinal changes resolved spontaneously and may represent a normal developmental stage in infants.
Area of Science:
- Ophthalmology
- Neonatology
- Genetics
Background:
- Spinal muscular atrophy (SMA) is a genetic neuromuscular disease.
- Ophthalmologic monitoring is crucial for infants with SMA, especially those receiving risdiplam therapy.
- Potential retinal toxicity from risdiplam necessitates careful observation.
Purpose of the Study:
- To describe the occurrence and clinical course of cystoid macular edema (CME) in term infants with genetically confirmed presymptomatic spinal muscular atrophy (SMA).
- To evaluate potential risdiplam-related retinal toxicity through ophthalmologic monitoring.
- To characterize macular changes in infants with SMA using optical coherence tomography (OCT).
Main Methods:
- A retrospective observational case series was conducted.
- Eight term infants with presymptomatic SMA were included.
- Serial handheld spectral-domain optical coherence tomography (OCT) was performed between 3 and 28 weeks of age.
Main Results:
- Cystoid macular edema (CME) was detected in 2 of 8 infants (25%).
- Intraretinal cysts were bilateral, symmetrical, confined to the inner nuclear layer, and resolved spontaneously by 4-5 months.
- No subretinal fluid or other structural abnormalities were noted, and findings were not associated with visual symptoms.
Conclusions:
- The observed retinal changes appear to be a benign, self-limiting process.
- The findings suggest that inner retinal cystic changes might represent a physiologic stage of postnatal development.
- Further research with normative neonatal OCT data is needed to definitively determine the cause of these retinal changes.
Purpose:
To describe the presence and clinical course of cystoid macular edema (CME) in term infants with genetically confirmed presymptomatic spinal muscular atrophy (SMA) undergoing ophthalmologic monitoring for potential risdiplam-related retinal toxicity.
Methods:
A retrospective observational case series was conducted at Sydney Children's Hospital, a participating site in a trial for risdiplam. Eight term infants underwent serial handheld spectral-domain optical coherence tomography (OCT) between 3 and 28 weeks of age. OCT images were reviewed for signs of retinal toxicity and morphological changes.
Results:
CME was observed in 2 of 8 infants (25%), one of whom had not yet initiated risdiplam therapy. In both cases, intraretinal cysts were bilateral, symmetrical, confined to the inner nuclear layer, and resolved spontaneously by 4 to 5 months of age. No subretinal fluid or other structural abnormalities were observed. These findings were not associated with visual symptoms or adverse outcomes.
Conclusions:
The spontaneous resolution and confinement of cystic changes to the inner retina in these infants suggest a benign, self-limiting process potentially unrelated to risdiplam. However, the small sample size and absence of a comparison group mean the data are insufficient to determine whether these changes are physiologic, associated with SMA, or treatment related. These findings highlight the need for normative neonatal OCT data to guide interpretation of early retinal findings and support the cautious hypothesis that inner retinal cystic changes may represent a physiologic stage of postnatal development.
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Teratogenicity
Sexually Transmitted Infections
Diabetic Retinopathy

